<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00650637</url>
  </required_header>
  <id_info>
    <org_study_id>A4301004</org_study_id>
    <nct_id>NCT00650637</nct_id>
  </id_info>
  <brief_title>A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea</brief_title>
  <official_title>A Randomized, Open-Label, Third-Party Blinded Study for the Prophylaxis and Treatment of Nelfinavir-associated Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the efficacy and safety of calcium carbonate for
      the prevention of nelfinavir-associated diarrhea and to evaluate the efficacy and safety of
      calcium carbonate in combination with loperamide for the treatment of nelfinavir-associated
      diarrhea.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was prematurely discontinued due to administrative reasons on August 18, 2003. There
    were no safety concerns that led to the decision to terminate.
  </why_stopped>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who experienced protocol-defined diarrhea in each treatment group during study</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first occurrence of protocol-defined diarrhea</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The outcome of calcium carbonate plus loperamide in treating subjects who experienced diarrhea</measure>
    <time_frame>Weeks 2, 4, 6, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of diarrhea collected from the subject daily diary during the study will be summarized before and after subjects receive calcium carbonate plus loperamide</measure>
    <time_frame>Weeks 2, 4, 6, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluations including physical exam, weight and vital signs measurements</measure>
    <time_frame>Screening, baseline, Weeks 2, 4, 6, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment of laboratory parameters</measure>
    <time_frame>Screening, baseline, Weeks 4, 8, and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate</intervention_name>
    <description>Calcium carbonate 500 mg oral tablet twice a day; given in combination with the following antiretroviral combination: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day); If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly; All study drugs continued through to Week 12</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nelfinavir</intervention_name>
    <description>1250 mg twice a day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Viracept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamivudine</intervention_name>
    <description>lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>loperamide</intervention_name>
    <description>If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly;</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Calcium carbonate not administered</intervention_name>
    <description>Prophylaxis with calcium carbonate not administered in this group; The following antiretroviral combination was administered: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nelfinavir</intervention_name>
    <description>nelfinavir 1250 mg twice a day</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Viracept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamivudine + zidovudine</intervention_name>
    <description>lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Antiretroviral-naive patients with HIV-1 infection

          -  not more than 2 loose stools per day or any preexisting or emerging medical condition
             that would interfere with the evaluation of therapeutic response of the study drug

          -  No antidiarrheal medication within 7 days prior to entry

        Exclusion Criteria:

          -  Greater than or equal to 2 loose stools per day lasting 2 or more days within 7 days
             prior to study entry

          -  Bloody stools within 7 days prior to study entry

          -  Any unstable or severe intercurrent medical condition, including active opportunistic
             infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4301004&amp;StudyName=A%20Study%20to%20Determine%20Effective%20Prophylaxis%20and%20Treatment%20of%20Nelfinavir-Associated%20Diarrhea.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2008</study_first_submitted>
  <study_first_submitted_qc>April 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2008</study_first_posted>
  <last_update_submitted>June 3, 2011</last_update_submitted>
  <last_update_submitted_qc>June 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Loperamide</mesh_term>
    <mesh_term>Antidiarrheals</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

